Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KLK7 | P49862 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176286 | 0.82 | S1PR3 (0.49) | S1PR3GAAKLK7ALDH1A1S1PR1 | |
| SCHEMBL19975216 | 0.75 | SMN1; SMN2 (0.44) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL19975309 | 0.74 | SMN1; SMN2 (0.44) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL19974966 | 0.74 | SMN1; SMN2 (0.44) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL19974913 | 0.71 | EPHX1 (0.43) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL19974820 | 0.71 | PTGIR (0.42) | GAAALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL19974824 | 0.71 | SMN1; SMN2 (0.41) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL13631421 | 0.69 | HIF1A (0.60) | GAAALDH1A1TSHR | |
| SCHEMBL19975197 | 0.68 | TDP1 (0.37) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL19975438 | 0.67 | SMN1; SMN2 (0.43) | GAAALDH1A1SMN1; SMN2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | S1PR3 1257/4885GAA 75/4885KLK7 3664/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | S1PR3 1437/4885GAA 107/4885KLK7 3632/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | S1PR3 1257/4885GAA 75/4885KLK7 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.